Also trades as: 0R3M.L (LSE) · $vol 0M
VVY.AS AMS
Vivoryon Therapeutics N.V.
1W: -0.9%
1M: -2.6%
3M: -6.0%
YTD: -23.6%
1Y: -34.9%
3Y: -90.3%
5Y: -94.0%
€1.08 ($1.21)
-0.02 (-1.82%)
Weekly Expected Move ±2.5%
€1
€1
€1
€1
€1
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Cash Flow Trends
Operating Cash Flow
-$19M
+11.0% ▲
Capital Expenditures
$2K
+99.6% ▲
5Y CAGR: -46.8%
Free Cash Flow
-$19M
+13.1% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$9M
-15.1% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$17M | -$13M | -$28M | -$28M | -$21M |
| Depreciation & Amort. | $146K | $165K | $161K | $167K | $147K |
| Stock-Based Comp. | $159K | $2M | $3M | $4M | $0 |
| Change in Working Capital | $2M | -$579K | $207K | -$235K | -$1M |
| Other Non-Cash Items | $432K | -$3M | $3M | $3M | $2M |
| Operating Cash Flow | -$14M | -$11M | -$22M | -$22M | -$19M |
| — Investing Activities — | |||||
| Capital Expenditures | -$640K | -$28K | -$13K | -$14K | -$2K |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | $0 | $0 | $0 | -$19M | $0 |
| Investment Sales | $0 | $0 | $0 | $9M | $10M |
| Other Investing | $0 | $0 | $0 | -$500K | $0 |
| Investing Cash Flow | -$640K | -$28K | -$13K | -$11M | $10M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$90K | -$90K | -$92K | -$94K | -$57K |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $0 | $0 | -$3M | -$2M | $0 |
| Financing Cash Flow | -$90K | -$827K | $33M | $24M | -$57K |
| Net Change in Cash | -$15M | -$12M | $12M | -$8M | -$9M |
| Cash End of Period | $26M | $15M | $27M | $19M | $9M |
| Free Cash Flow | -$15M | -$11M | -$22M | -$22M | -$19M |